1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for MRD (Minimal Residual Disease) Testing by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for MRD (Minimal Residual Disease) Testing by Country/Region, 2018, 2022 & 2029
2.2 MRD (Minimal Residual Disease) Testing Segment by Type
2.2.1 Flow Cytometry
2.2.2 Polymerase Chain Reaction (PCR)
2.2.3 Next-Generation Sequencing (NGS)
2.3 MRD (Minimal Residual Disease) Testing Sales by Type
2.3.1 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Type (2018-2023)
2.3.2 Global MRD (Minimal Residual Disease) Testing Revenue and Market Share by Type (2018-2023)
2.3.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Type (2018-2023)
2.4 MRD (Minimal Residual Disease) Testing Segment by Application
2.4.1 Specialty Clinics and Hospitals
2.4.2 Diagnostic Laboratories
2.4.3 Research Institutions
2.5 MRD (Minimal Residual Disease) Testing Sales by Application
2.5.1 Global MRD (Minimal Residual Disease) Testing Sale Market Share by Application (2018-2023)
2.5.2 Global MRD (Minimal Residual Disease) Testing Revenue and Market Share by Application (2018-2023)
2.5.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Application (2018-2023)
3 Global MRD (Minimal Residual Disease) Testing by Company
3.1 Global MRD (Minimal Residual Disease) Testing Breakdown Data by Company
3.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Company (2018-2023)
3.1.2 Global MRD (Minimal Residual Disease) Testing Sales Market Share by Company (2018-2023)
3.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Company (2018-2023)
3.2.1 Global MRD (Minimal Residual Disease) Testing Revenue by Company (2018-2023)
3.2.2 Global MRD (Minimal Residual Disease) Testing Revenue Market Share by Company (2018-2023)
3.3 Global MRD (Minimal Residual Disease) Testing Sale Price by Company
3.4 Key Manufacturers MRD (Minimal Residual Disease) Testing Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers MRD (Minimal Residual Disease) Testing Product Location Distribution
3.4.2 Players MRD (Minimal Residual Disease) Testing Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for MRD (Minimal Residual Disease) Testing by Geographic Region
4.1 World Historic MRD (Minimal Residual Disease) Testing Market Size by Geographic Region (2018-2023)
4.1.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Geographic Region (2018-2023)
4.1.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic MRD (Minimal Residual Disease) Testing Market Size by Country/Region (2018-2023)
4.2.1 Global MRD (Minimal Residual Disease) Testing Annual Sales by Country/Region (2018-2023)
4.2.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue by Country/Region (2018-2023)
4.3 Americas MRD (Minimal Residual Disease) Testing Sales Growth
4.4 APAC MRD (Minimal Residual Disease) Testing Sales Growth
4.5 Europe MRD (Minimal Residual Disease) Testing Sales Growth
4.6 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales Growth
5 Americas
5.1 Americas MRD (Minimal Residual Disease) Testing Sales by Country
5.1.1 Americas MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
5.1.2 Americas MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
5.2 Americas MRD (Minimal Residual Disease) Testing Sales by Type
5.3 Americas MRD (Minimal Residual Disease) Testing Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC MRD (Minimal Residual Disease) Testing Sales by Region
6.1.1 APAC MRD (Minimal Residual Disease) Testing Sales by Region (2018-2023)
6.1.2 APAC MRD (Minimal Residual Disease) Testing Revenue by Region (2018-2023)
6.2 APAC MRD (Minimal Residual Disease) Testing Sales by Type
6.3 APAC MRD (Minimal Residual Disease) Testing Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe MRD (Minimal Residual Disease) Testing by Country
7.1.1 Europe MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
7.1.2 Europe MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
7.2 Europe MRD (Minimal Residual Disease) Testing Sales by Type
7.3 Europe MRD (Minimal Residual Disease) Testing Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa MRD (Minimal Residual Disease) Testing by Country
8.1.1 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Country (2018-2023)
8.1.2 Middle East & Africa MRD (Minimal Residual Disease) Testing Revenue by Country (2018-2023)
8.2 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Type
8.3 Middle East & Africa MRD (Minimal Residual Disease) Testing Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of MRD (Minimal Residual Disease) Testing
10.3 Manufacturing Process Analysis of MRD (Minimal Residual Disease) Testing
10.4 Industry Chain Structure of MRD (Minimal Residual Disease) Testing
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 MRD (Minimal Residual Disease) Testing Distributors
11.3 MRD (Minimal Residual Disease) Testing Customer
12 World Forecast Review for MRD (Minimal Residual Disease) Testing by Geographic Region
12.1 Global MRD (Minimal Residual Disease) Testing Market Size Forecast by Region
12.1.1 Global MRD (Minimal Residual Disease) Testing Forecast by Region (2024-2029)
12.1.2 Global MRD (Minimal Residual Disease) Testing Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global MRD (Minimal Residual Disease) Testing Forecast by Type
12.7 Global MRD (Minimal Residual Disease) Testing Forecast by Application
13 Key Players Analysis
13.1 ICON plc
13.1.1 ICON plc Company Information
13.1.2 ICON plc MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.1.3 ICON plc MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 ICON plc Main Business Overview
13.1.5 ICON plc Latest Developments
13.2 ArcherDX(Invitae)
13.2.1 ArcherDX(Invitae) Company Information
13.2.2 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.2.3 ArcherDX(Invitae) MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 ArcherDX(Invitae) Main Business Overview
13.2.5 ArcherDX(Invitae) Latest Developments
13.3 ARUP Laboratories
13.3.1 ARUP Laboratories Company Information
13.3.2 ARUP Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.3.3 ARUP Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 ARUP Laboratories Main Business Overview
13.3.5 ARUP Laboratories Latest Developments
13.4 Asuragen
13.4.1 Asuragen Company Information
13.4.2 Asuragen MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.4.3 Asuragen MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Asuragen Main Business Overview
13.4.5 Asuragen Latest Developments
13.5 Cergentis B.V.
13.5.1 Cergentis B.V. Company Information
13.5.2 Cergentis B.V. MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.5.3 Cergentis B.V. MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Cergentis B.V. Main Business Overview
13.5.5 Cergentis B.V. Latest Developments
13.6 Bio-Rad Laboratories
13.6.1 Bio-Rad Laboratories Company Information
13.6.2 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.6.3 Bio-Rad Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bio-Rad Laboratories Main Business Overview
13.6.5 Bio-Rad Laboratories Latest Developments
13.7 Mission Bio
13.7.1 Mission Bio Company Information
13.7.2 Mission Bio MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.7.3 Mission Bio MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Mission Bio Main Business Overview
13.7.5 Mission Bio Latest Developments
13.8 Guardant Health
13.8.1 Guardant Health Company Information
13.8.2 Guardant Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.8.3 Guardant Health MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Guardant Health Main Business Overview
13.8.5 Guardant Health Latest Developments
13.9 Invivoscribe
13.9.1 Invivoscribe Company Information
13.9.2 Invivoscribe MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.9.3 Invivoscribe MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Invivoscribe Main Business Overview
13.9.5 Invivoscribe Latest Developments
13.10 LabCorp
13.10.1 LabCorp Company Information
13.10.2 LabCorp MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.10.3 LabCorp MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 LabCorp Main Business Overview
13.10.5 LabCorp Latest Developments
13.11 Inivata
13.11.1 Inivata Company Information
13.11.2 Inivata MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.11.3 Inivata MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Inivata Main Business Overview
13.11.5 Inivata Latest Developments
13.12 Natera
13.12.1 Natera Company Information
13.12.2 Natera MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.12.3 Natera MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Natera Main Business Overview
13.12.5 Natera Latest Developments
13.13 NeoGenomics Laboratories
13.13.1 NeoGenomics Laboratories Company Information
13.13.2 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.13.3 NeoGenomics Laboratories MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 NeoGenomics Laboratories Main Business Overview
13.13.5 NeoGenomics Laboratories Latest Developments
13.14 Opko Health
13.14.1 Opko Health Company Information
13.14.2 Opko Health MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.14.3 Opko Health MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Opko Health Main Business Overview
13.14.5 Opko Health Latest Developments
13.15 Quest Diagnostics
13.15.1 Quest Diagnostics Company Information
13.15.2 Quest Diagnostics MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.15.3 Quest Diagnostics MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Quest Diagnostics Main Business Overview
13.15.5 Quest Diagnostics Latest Developments
13.16 Sysmex Corporation
13.16.1 Sysmex Corporation Company Information
13.16.2 Sysmex Corporation MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.16.3 Sysmex Corporation MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Sysmex Corporation Main Business Overview
13.16.5 Sysmex Corporation Latest Developments
13.17 Adaptive Biotechnologies
13.17.1 Adaptive Biotechnologies Company Information
13.17.2 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Product Portfolios and Specifications
13.17.3 Adaptive Biotechnologies MRD (Minimal Residual Disease) Testing Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Adaptive Biotechnologies Main Business Overview
13.17.5 Adaptive Biotechnologies Latest Developments
14 Research Findings and Conclusion
| ※参考情報 MRD（最小残存病変）検査は、がん治療における重要な技術の一つであり、特に血液腫瘍の診断と治療管理において大きな役割を果たしています。MRDとは、患者の体内に残存する微小ながん細胞のことを指し、通常の検査では検出できないごく少量の腫瘍細胞を指摘します。この検査は、がんの再発リスクを評価するためや、治療効果をモニタリングするために使用されます。 MRD検査の特徴としては、非常に高い感度を持つことが挙げられます。従来の画像診断や血液検査では発見できない程度の微小な腫瘍細胞を検出できるため、早期の再発を捉えることが可能です。この特性により、患者の治療の進捗をリアルタイムで把握し、必要に応じて治療方針を見直すことができます。また、MRD検査は再発の早期発見だけでなく、治療後の監視にも役立ちます。特に急性リンパ性白血病（ALL）や慢性骨髄性白血病（CML）、悪性リンパ腫などの血液疾患において、MRDの状態を追跡することは非常に重要です。 MRD検査の種類として、大きく分けて二つの技術が存在します。一つは「PCR（ポリメラーゼ連鎖反応）」を用いる方法で、もう一つは「フローサイトメトリー」と呼ばれる技術です。PCR検査は、特定の遺伝子や遺伝子再構成をターゲットにして微小残存病変を増幅して検出します。この方法は非常に高感度であり、少量のがん細胞を検出するのに適しています。もう一方のフローサイトメトリーは、特定のマーカーで腫瘍細胞を識別し、細胞の数を測定するものです。この技術もまた、高速で大量の細胞を解析することができ、臨床での応用が広がっています。 MRD検査の用途は多岐にわたります。主な用途としては、治療効果の評価、再発リスクの評価、さらには治療の方針を決定するための補助的な情報を提供することが挙げられます。たとえば、MRDが陰性であれば、患者は比較的良好な予後が期待できるとされ、新たな治療介入の必要がないかもしれません。反対にMRDが陽性であれば、再発の可能性が高まるため、追加の治療が必要となる場合があります。 MRD検査は、特に小児患者においてその効果が見込まれています。小児急性リンパ性白血病の治療において、MRDの状態を評価することは、治療の成功や再発のリスクを減少させるために不可欠な要素です。MRDの検査は、患者の個々の状況に応じた個別化医療の実現にも寄与します。 関連する技術としては、次世代シーケンシング（NGS）技術も挙げられます。NGSは、DNAやRNAの配列情報を迅速かつ大量に解析することができる手法で、MRD検査における感度向上に寄与しています。従来のPCR法では検出できない微小な変異や再構成も捉えることができるため、将来的にはMRD市場においてさらに強力なツールとなることが期待されています。 MRD検査は、その精度や応用の広がりから、血液がん治療における重要な指標となっています。しかし、MRD検査の結果は一つの要因に過ぎないため、臨床的な判断は常に多角的な視点から行われることが求められます。患者の全体的な健康状態や他の検査結果と合わせて考慮し、最適な治療戦略を見つけることが、MRD検査の重要な目的となります。 最小残存病変検査は、がんと闘う患者にとって非常に価値のある情報を提供するものですが、検査結果に基づく治療計画の策定には、専門家の意見やチーム医療が不可欠です。今後も医療技術の進化が期待される中、MRD検査は患者の生存率向上に寄与する大きな可能性を秘めています。したがって、MRD検査に関する知識や技術の進展は、がん治療の新たな道を切り開くものと考えられます。 |
